Menu
Not yet recruiting NCT07743476

Quantitative Marrow Imaging, Marrow Reserve, And Clinical Outcomes In Patients Undergoing Radiotherapy For Hematologic And Related Disorders

Observational Quantitative Marrow Imaging Marrow Reserve Clinical Outcomes Radiotherapy

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: data collection.
Who it may be relevant to
Registry conditions: Quantitative Marrow Imaging, Marrow Reserve, Clinical Outcomes, Radiotherapy. Basic parameters: No limits · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

To create a registry for people who are undergoing or previously underwent radiotherapy for hematologic or related disorders.

Interventions

  • Other data collection
    The study will collect clinical, imaging, laboratory, treatment, and outcome data from the electronic medical record, radiation treatment planning systems, imaging archives, and other institutional clinical databases

Primary outcome measures

  • Safety and adverse events (AEs). [Time frame: Through study completion; an average of 1 year.]

Eligibility criteria

Inclusion criteria

  • Undergoing or previously underwent radiotherapy at The University of Texas MD Anderson Cancer Center for hematologic or related disorders.
  • Available clinical, imaging, laboratory, treatment, and/or outcome data relevant to study objectives.
  • Ability to provide informed consent for prospective participation, when applicable.

Exclusion criteria

Participants meeting any of the following criteria will be excluded:

  • Inability to provide informed consent, or when applicable, the absence of a legally authorized representative able to provide consent for prospective participation.
  • Insufficient clinical information available to support study objectives.
  • Pregnant women

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

United States · 1 center
  • UT MD Anderson Cancer Center — Houston

Identifiers

NCT: NCT07743476 · 2026-0958 · NCI-2026-05811

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗